The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world utilization pattern of pexidartinib in patients with tenosynovial giant cell tumor (TGCT).
 
Feng Lin
Employment - Daiichi Sankyo Pharmaceutical
Stock and Other Ownership Interests - Daiichi Sankyo Pharmaceutical
Research Funding - Daiichi Sankyo Pharmaceutical
 
Jenny Tse
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - Daiichi Sankyo (Inst)
 
Nazneen Fatima Shaikh
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical (Inst)
Research Funding - Daiichi Sankyo Pharmaceutical (Inst)
 
Elizabeth J Wang
Employment - IQVIA
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - Daiichi Sankyo (Inst)
 
Aimee Near
Consulting or Advisory Role - IQvia (Inst)
 
Jackie Kwong
Employment - Daiichi Sankyo, Inc.
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; Servier
Research Funding - AmMax Bio (Inst); Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03